Lobe Sciences Ltd. (LOBE.CN)
| Previous Close | 0.0150 |
| Open | 0.0000 |
| Bid | 0.0150 x N/A |
| Ask | 0.0200 x N/A |
| Day's Range | 0.0000 - 0.0000 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 33,616 |
| Market Cap | 1.583M |
| Beta (5Y Monthly) | 2.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0300 |
| Earnings Date | Apr 26, 2024 - Apr 30, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireLobe Sciences Provides Company Review of 2023
VANCOUVER, British Columbia, January 08, 2024--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today provided an update from the Company on its progress and achievements in 2023.
Business WireLobe Sciences Provides Update on L-130 Clinical Program
VANCOUVER, British Columbia, December 07, 2023--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today provided an update from the Company’s lead clinical program, L-130, a proprietary stabilized psilocin conjugate drug candidate. The Phase 1 study (NCT06035900) was an open label clinical trial in 10 normal and healthy individuals designed to determine the safety and pharmaco
Business WireLobe Sciences Provides Update on L-130 Oral Psilocin Compound
VANCOUVER, British Columbia, December 05, 2023--Lobe Sciences Reports 12 Months Stability for Lead Psilocin Drug Candidate (L-130).
